Ekso Bionics Holdings Inc (NASDAQ: EKSO)’s stock price has soared by 5.81 in relation to previous closing price of 1.29. Nevertheless, the company has seen a loss of -3.87% in its stock price over the last five trading days. Seeking Alpha reported 2024-03-04 that Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q4 2023 Earnings Conference Call March 4, 2024 4:30 PM ET Company Participants Matt Steinberg – Finn Partners Scott Davis – Chief Executive Officer Jerome Wong – Chief Financial Officer Jason Jones – Chief Operating Officer Conference Call Participants Swayampakula Ramakanth – H.C. Wainwright Ben Haynor – Alliance Global Partners Operator Greetings, and welcome to the Ekso Bionics’ Fourth Quarter 2023 Financial Results Conference Call.
Is It Worth Investing in Ekso Bionics Holdings Inc (NASDAQ: EKSO) Right Now?
The 36-month beta value for EKSO is also noteworthy at 1.64. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for EKSO is 14.93M, and at present, short sellers hold a 0.90% of that float. The average trading volume of EKSO on April 12, 2024 was 169.97K shares.
EKSO’s Market Performance
EKSO’s stock has seen a -3.87% decrease for the week, with a -3.19% drop in the past month and a -31.75% fall in the past quarter. The volatility ratio for the week is 8.80%, and the volatility levels for the past 30 days are at 7.59% for Ekso Bionics Holdings Inc The simple moving average for the last 20 days is -1.41% for EKSO’s stock, with a simple moving average of -3.05% for the last 200 days.
EKSO Trading at -19.81% from the 50-Day Moving Average
After a stumble in the market that brought EKSO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.37% of loss for the given period.
Volatility was left at 7.59%, however, over the last 30 days, the volatility rate increased by 8.80%, as shares surge +3.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.86% lower at present.
During the last 5 trading sessions, EKSO fell by -1.41%, which changed the moving average for the period of 200-days by +3.70% in comparison to the 20-day moving average, which settled at $1.3870. In addition, Ekso Bionics Holdings Inc saw -45.40% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EKSO starting from Lathan Corinna, who purchase 4,032 shares at the price of $1.24 back on Nov 02 ’23. After this action, Lathan Corinna now owns 147,990 shares of Ekso Bionics Holdings Inc, valued at $5,005 using the latest closing price.
Lathan Corinna, the Director of Ekso Bionics Holdings Inc, purchase 5,500 shares at $0.95 during a trade that took place back on Aug 23 ’23, which means that Lathan Corinna is holding 143,958 shares at $5,222 based on the most recent closing price.
Stock Fundamentals for EKSO
Current profitability levels for the company are sitting at:
- -0.83 for the present operating margin
- 0.5 for the gross margin
The net margin for Ekso Bionics Holdings Inc stands at -0.82. The total capital return value is set at -0.73. Equity return is now at value -79.89, with -43.53 for asset returns.
Based on Ekso Bionics Holdings Inc (EKSO), the company’s capital structure generated 0.34 points at debt to capital in total, while cash flow to debt ratio is standing at -1.87. The debt to equity ratio resting at 0.51. The interest coverage ratio of the stock is -47.52.
Currently, EBITDA for the company is -13.41 million with net debt to EBITDA at 0.11. When we switch over and look at the enterprise to sales, we see a ratio of 1.24. The receivables turnover for the company is 3.24for trailing twelve months and the total asset turnover is 0.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.49.
Conclusion
In summary, Ekso Bionics Holdings Inc (EKSO) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
